INTRODUCTION
Prostate cancer is a diverse disease with multiple treatment options and inconsistent outcomes. Risk stratification in patients with newly diagnosed prostate cancer allows physicians to choose the optimal treatment strategy for each patient. Even within the group of patients with high-risk prostate cancer, based on its classic definition, there remains significant heterogeneity in outcomes. While most high-risk patients respond favorably to local definitive therapy with curative intent, a subgroup of patients may progress and succumb to their cancer. Identifying these patients with very high-risk features is important, as they may benefit from multimodal therapy, targeting both the local and systemic components of disease. In the current review we discuss the appropriate definition of very-high-risk prostate cancer and recent advancements in the treatment of these patients, focusing primarily on those with locally advance disease (clinical stage T3b-T4) and lymph node metastases identified on pre-treatment imaging.
LITERATURE REVIEW METHODS
We searched the National Institute of Health MEDLINE database for all articles published in English between January 2000 and April 2016, with the following search terms: 'prostatic neoplasms' (MeSH Terms) AND ('high risk' (keyword) OR 'locally advanced' (keyword) OR 'node positive' (keyword)). Overall, 676 clinical trials or practice guidelines were found, the titles and abstracts of which were evaluated. Forty publications pertaining to the diagnosis and treatment of very-high-risk prostate cancer served as the basis for this review. Additional studies were extracted through reference lists of the latter.
RESULTS AND DISCUSSION
Defining very-high-risk prostate cancer The current definitions of high-risk prostate cancer include various patients with wide range of prognoses, each requiring a different treatment approach. 1 High-risk prostate cancer was initially coined by D'Amico et al. 2 as clinical T stage ⩾ T2c, or Gleason score (GS) ⩾ 8, or PSA 420 mg ml − 1 . Albeit broad, this definition was adopted by the American Urological Association. 3 In order to increase its specificity, the European Association of Urology (EAU) and National Comprehensive Cancer Network (NCCN) upgraded the risk level to include patients with clinical T stage ⩾ T3a; the PSA level and Gleason score retained the same high-risk threshold. 4, 5 However, when using these and other similar classifications, the 5-year progression-free survival (PFS) after radical prostatectomy (RP) alone is inconsistent and ranges from 50 to 80% questioning their utility in identifying patients at genuine risk of treatment failure. 6 Tumor GS may be used to refine the individual risk of relapse among high-risk patients. While GS ⩾ 8 is commonly used to define high-risk prostate cancer, previous reports have shown that patients with GS 8 have a lower risk of biochemical recurrence than those with GS 9-10, and that the outcome of men with GS 7 and a tertiary grade 5 did not differ significantly than that of patients with GS 9-10. [7] [8] [9] [10] [11] In these studies, the presence of any Gleason pattern 5 was an independent predictor of adverse outcome. 10 Furthermore, patients with high-grade prostate cancer (GS 8-10) and additional adverse pathological findings, including positive surgical margin, extracapsular extension and mostly seminal vesical invasion, were at a particularly high risk of biochemical recurrence after RP. 11, 12 In light of these findings the International Society of Uropathologists has recently adopted a revised Gleason grading system wherein GS 8 and GS 9-10 have been separated into two different prognostic groups. Patients with GS 9-10 should be considered to have more aggressive tumors, which likely warrant a multimodal treatment approach. 9 The role of pre-treatment PSA level as a determinant of veryhigh-risk disease has been evaluated by several studies. Izumi et al. reported that PSA levels exceeding 100 ng ml − 1 were not a significant predictor of overall or cancer-specific mortality (CSM), whereas the presence of clinical metastasis and high GS in this setting did predict survival. Patients who were considered at lower risk (M0 and GS o9) had a 5-year cancer-specific survival (CSS) rate of 100% compared with 58% in the very-high-risk group (M1 and GS ⩾ 9). 13 Ang et al. reported the outcome of 241 patients with PSA 4100 ng ml − 1 at diagnosis. The overall survival (OS) in their cohort was 29% at 5 years and 18% at 10 years, significantly inferior to patients with lower PSA levels at presentation. Furthermore, there was a linear association between PSA level and risk of mortality up to a threshold of 200 ng ml − 1 , beyond which mortality plateaued. 14 Thus, while higher PSA levels, in particular 4100 ng ml − 1 , predict a worse outcome, the decision whether to use a multimodal approach in order to achieve local control should rely primarily on the GS and metastatic status rather than the PSA level itself.
In an attempt to improve the classification of high-risk prostate cancer using multiple disease characteristics, Sphan et al. studied 712 patients with prostate cancer and PSA 420, and found that combining additional risk factors (for example, GS 8-10 and clinical stage T3-T4) at presentation was associated with unfavorable histopathology and worse cancer-specific outcome (Table 1) . 15 Similarly, Walz et al. and others demonstrated that patients with two or more high-risk features (PSA 420, GS 8-10 and cT3-4) had worse biochemical recurrence-free survival and prostate CSS compared with patients with a single high-risk feature. 16, 17 Researchers from Johns Hopkins University utilized commonly used clinical variables to distinguish a group of men with very-high-risk prostate cancer who suffered the worst outcome despite aggressive treatment. These patients, representing 15% of the total NCCN high-risk cohort, had primary Gleason pattern 5, or ⩾ 5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. In this group, biochemical recurrence-free survival, metastasis-free survival and CSS were 21%, 37% and 62% at 10 years, respectively. 18 Similarly, the pre-operative criteria that best identified NCCN high-risk patients likely to experience relapse within 1 year of surgery were Gleason pattern 5 on biopsy or ⩾ 4 cores containing pattern 4 (odds ratio 3.17, P o0.001). These men were also at higher risk of metastatic progression (adjusted hazard ratio (HR) 3.04, P o0.001) and cancer-specific death (adjusted HR 3.27, P o0.001). 19 In their 2014 guidelines, the NCCN defined very-high-risk prostate cancer as tumors invading the seminal vesicles (T3b) or adjacent structures (T4) ( Table 1) . 5 Nomograms derived in order to improve risk stratification of patients with prostate cancer were initially developed based on diverse patient populations; however, these algorithms may improve risk stratification within the group of high-risk patients. The Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score 20 was evaluated in the context of high-risk patients undergoing RP with or without radiation therapy (RT). 21, 22 Patients with high CAPRA-S scores (⩾6) had a significantly higher risk of CSM and a higher risk of biochemical recurrence following RT either in the adjuvant or salvage setting, thus defining a group of patients with very-high-risk disease. 21, 22 Recent advancements in the molecular understanding of prostate cancer has led to the development of multiple molecular tests, which may improve disease risk stratification. 23 In the context of high-risk prostate cancer, the Decipher test, an assay based on 22 markers related to cell proliferation, differentiation, androgen signaling, motility and immune modulation, may independently predict the development of metastatic disease and CSM in patients treated with RP either with or without adjuvant or salvage RT. 21, [23] [24] [25] Furthermore, combining the Decipher genomic classifier with validated clinicopathologic risk models improved their accuracy in predicting adverse outcome. 21, 24, 25 Future studies will refine the indications for the use of molecular testing and reveal additional markers, which may identify very-high-risk patients who will benefit from aggressive multimodal therapy. 23 Lymph node involvement was traditionally considered to represent systemic disease, associated frequently with poor prognosis. In fact, the American Joint Committee on Cancer staging system still categorizes patients with lymph node involvement and bone metastases equally as stage IV disease. 26 However, the finding of microscopic nodal involvement at surgery may portend a better outcome than visceral or bone metastasis, particularly if the number of involved nodes is accounted for. Cheng et al. 27 reported that patients with a single positive lymph node who were treated with RP and immediate adjuvant hormonal therapy had a prognosis comparable to that of patients without nodal involvement. Briganti et al. 28 found that patients with 2 or less positive nodes treated with RP, extended pelvic lymph node dissection and adjuvant therapy (hormonal blockade alone or in combination with RT) had a significantly better CSS at 15 years of follow-up than those with 42 nodes (84% vs 62%, P o0.001). Recently, Touijer et al. reported that among patients with lymph node metastases treated surgically without further adjuvant therapy, a subset of men with Gleason score o8 and 2, or less, positive lymph nodes had a particularly favorable outcome at 10 years. 29 These findings suggest that not all cases of nodal involvement should be considered uniformly as having ominous Table 1 . Definition of very-high-risk prostate cancer in the current literature
Source Definition
Spahn et al.
15
PSA 420 ng ml − 1 in combination with ⩾ 1 other high-risk factor (GS 8-10 and cT3-4) Walz et al.
16
⩾ 2 high-risk features (PSA 420 ng ml − 1 , GS 8-10 and cT3-4) Joniau et al.
17
GS 8-10 in combination with ⩾ 1 other high-risk factor (PSA 420 ng ml − 1 and cT3-4) Sundi et al. a Definition used to describe high-risk locally advanced tumors.
Treatment of very-high-risk prostate cancer R Mano et al systemic disease, questioning the validity of the current staging system and treatment paradigms in this setting. While it is unclear whether microscopic lymph node involvement on final pathology can be deemed comparable to clinical nodal disease identified by modern imaging techniques, the recent EAU guidelines include cN+ patients within the category of high-risk locally advanced disease amenable for local definitive management within a multimodal approach (Table 1) . 30 Role of modern imaging in assessment of high-risk prostate cancer Numerous studies have demonstrated the incremental value of multiparametric magnetic resonance imaging (mpMRI) in evaluating prostate cancer (Table 2) . 31, 32 Pre-treatment assessment with diffusion-weighted MRI and use of MRI-guided biopsy have been shown to differentiate between patients with low-risk and those with intermediate/high-risk tumors with reference to the specimen Gleason score. [33] [34] [35] In another study evaluating the performance characteristics of 3 T mpMRI, the positive predictive value for identifying extraprostatic extension was highest in the high-risk cohort, approaching 89%. In fact, mpMRI was found to be the best preoperative predictor of extraprostatic extension with an odds ratio of 10.3. 36 In light of these findings the EAU guidelines recommend a prostate mpMRI for local staging of high-risk localized or locally advanced prostate cancer. 30 Prostate-specific membrane antigen (PSMA), is a type II transmembrane protein overexpressed in nearly all prostate cancer cells and its use as a tracer during positron emission tomography (PET) scan has recently emerged as a novel promising imaging modality in prostate cancer (Table 2) . 37, 38 Because PET PSMA can improve identification of systemic or recurrent disease 37 , it would seem reasonable to explore its use in local staging of men with very-high-risk prostate cancer. In a group of patients with intermediate to high-risk disease, Maurer et al. reported a sensitivity of 66% and specificity of 99% for lymph node staging with 68Ga-PSMA-PET. 39 The corresponding performance characteristics of computed tomography, MRI and PETcholine were substantially inferior. [40] [41] [42] [43] Within a very-high-risk setting, the use of PET PSMA may facilitate the identification of minimal pelvic nodal involvement potentially suitable for definitive local treatment while avoiding possible morbidity in those with widespread systemic disease.
Treatment of patients with locally advanced prostate cancer (cT3b-cT4) Radical prostatectomy. While in most high-risk patients surgery is performed with curative intent, in the setting of clinical T3b-T4 prostate cancer, RP can also be considered for 'debulking' the primary tumor thereby enhancing local control (Table 3) . Experienced surgeons often use the information provided by MRI Values for detecting ECE and SVI were obtained when using a 11C-choline PET combined with computed tomography.
d Values for detecting ECE and SVI were obtained when using PET-PSMA combined with computed tomography. The study was underpowered to evaluate the endpoints of metastasis-free survival and overall survival.
Treatment of very
d Patients with cT3-4 disease represent 90% of the study cohort. e 78% of patients had a T3 disease. f The trial was terminated prematurely due to a high rate of thromboembolic events in the chemotherapy arm.
g Represents the number of patients with newly diagnosed high-risk N0M0 disease and the total number of patients included in the study. h All patients underwent a staging pelvic lymph node dissection.
Treatment of very-high-risk prostate cancer combined with their own subjective assessment by digital rectal examination to discern tumor resectability and discuss preemptively the feasibility of unilateral/bilateral nerve sparing vs killing of the neurovascular bundles. In a Surveillance Epidemiology and End Results-based study, Johnstone et al. evaluated the outcome of patients with clinical stage T4 prostate cancer, with or without lymph node involvement, and otherwise no evidence of bone or visceral metastasis. Only a minority of these patients (7%), more commonly the younger, underwent RP alone or in combination with RT and androgen deprivation therapy (ADT). In this unique very-high-risk group, treatment of the primary tumor (either by surgery or radiation) was associated with improved oncologic outcome compared with ADT alone or no treatment. This difference was evident mostly in those with regional lymph node involvement. 44 Moltzahn et al. evaluated a multi-institutional cohort of 266 patients with very-high-risk locally advanced prostate cancer (cT3b-4) treated surgically. Despite the adverse pathological features, the 10-year CSM was relatively low (5.6-12.9%), and affected by comorbidity status and age. In healthy patients (Charlson comorbidity index o1) CSM did not differ among age groups, suggesting RP may be appropriate even in older age. However, in sicker patients (Charlson comorbidity index ⩾ 1) the risk of dying from causes other than prostate cancer was high and CSM low questioning the incremental benefit of surgical therapy in this setting. 45 As for the surgical approach, with adequate experience, use of robotic surgery in patients with locally advanced disease appears to be comparable to traditional open RP. 46 Whether patients with locally advanced tumors should be offered additional local therapy (RT) or neoadjuvant/adjuvant hormonal therapy before or immediately after surgery has been widely investigated. Three randomized controlled trials have established the role of adjuvant and salvage RT for patients with high risk of local failure (Table 3) . [47] [48] [49] [50] [51] [52] Ongoing clinical trials will help clarify whether RT is more effective as an adjuvant or salvage treatment, and assess the value of combined therapy with ADT. Optimal RT dose, targets and field size are yet to be decided. 53 Taken together, surgery appears to have a critical role in men with very-high-risk prostate cancer as part of a multimodal comprehensive approach. The latter has been mirrored in the findings of Nezolosky et al. 54 who reported on increased rates of RP in men with T3N0M0 prostate cancer from 12 to 44% performed between 1998 and 2012.
RT combined with androgen deprivation. Multiple phase III studies have shown the efficacy of combining RT with ADT in locally advanced prostate cancer (Table 3) . [55] [56] [57] [58] [59] [60] [61] In a landmark paper, Bolla et al. compared the use of RT alone with RT and long-term (3 years) ADT in patients with locally advanced disease. Within the subgroup of patients with T3-4 disease, combined therapy was associated with better long-term loco-regional control, reduced rates of distant metastases and improved survival at a median follow-up of 9 years. 55, 56 No difference was observed in cardiovascular morbidity between the two arms. 56 A similar study, Radiation Therapy Oncology Group (RTOG) 85-31, evaluated the effectiveness of adjuvant ADT after definitive RT in patients with unfavorable prostate cancer (clinical stage T3, and regional lymph node involvement). At a median follow-up of 11 years the addition of ADT was associated with significantly improvement in 10-year OS (49% vs 39%, P = 0.002). 57, 58 Warde et al. randomized 1205 men with locally advanced cancers to receive lifelong ADT with or without RT to the prostate and pelvic nodes. Median follow-up was 6 years. The addition of RT was associated with an improved OS and minimal toxicity (7-year estimated OS 74% in the ADT/RT compared with 66% for ADT alone, P = 0.033). 59 Similarly, the SPCG-7/SFUO-3 study included 875 patients with locally advanced prostate cancer randomized to lifelong ADT with or without RT. At a median follow-up of 7.6 years, the estimated 10-year prostate CSM was 24% in the ADT alone group and 12% in the ADT/RT group (P o 0.001). Urinary, rectal and sexual morbidities were slightly more frequent in patients receiving RT. 60 Finally, the intergroup randomized study evaluated the role of adding RT to lifelong ADT in the treatment of locally advanced prostate cancer (clinical stage T3-4N0-xM0 disease, PSA 440 or 20-40 ng ml − 1 , and GS 8-10). At a median follow-up of 8 years, OS was significantly improved in patients receiving RT (HR = 0.7, 95% confidence interval 0.57-0.85, P o 0.001). A similar significant reduction was seen in prostate cancer related death albeit at the expense of a higher frequency of gastrointestinal toxicity. 61 These studies serve to establish the role of combining RT and ADT as standard of care in treatment of locally advanced prostate cancer. With regard to the duration of therapy, several phase III trials demonstrated that long-or intermediate-term ADT (24-36 months), especially in the presence of GS 8-10, is unequivocally superior to short-term ADT (⩽6 months) in terms of local control and patients' survival. [62] [63] [64] [65] [66] [67] The question of whether to include the pelvic lymph nodes within the radiation portals (whole pelvic radiation; WPRT) remains unsettled. Two phase III trials evaluated the use of WPRT vs prostate-only radiation (PORT) in high-risk node-negative disease.
, [68] [69] [70] The RTOG 9413 trial compared WPRT and PORT, both administrated with combined androgen suppression in a neoadjuvant or adjuvant form. At a median follow-up of~5 years, PFS was 54% for WPRT compared with 47% for PORT (P = 0.022); no OS advantage was observed 68 . In an update of this study, the use of WPRT showed a trend toward improved PFS when compared with PORT (P = 0.066). 69 The GETUG-01 trial compared WPRT with PORT in high-risk patients and demonstrated no differences in 5-year PFS rates (66% for WBRT and 65% for PORT, P = 0.34). No difference was observed in acute and late gastrointestinal toxicity or quality-of-life outcomes between the arms. 70 Using a higher radiation dose, Aizer et al. were able to demonstrate significantly improved biochemical recurrence-free survival rates favoring WBRT in a high-risk setting at the expense of an increase in early gastrointestinal toxicity. 71 In the largest study thus far, Amini et al. used the National Cancer Data Base to analyze the outcomes of 14 817 high-risk node-negative patients treated with WBRT vs PORT in a dose-escalated fashion. At a median follow-up of 81 months, no survival advantage was observed favoring WPRT. 72 Taken together, the data pertaining to WPRT in high-risk prostate cancer remain inconsistent, and thus additional studies and longer follow-up are required before establishing its role.
The role of chemotherapy in the high-risk setting. Three randomized controlled trials (CHAARTED 73 , GETUG-15 74 and STAMPEDE 75 ) have recently established a new standard for chemo-hormonal therapy administered at presentation in men with hormone-sensitive metastatic prostate cancer. The combined findings of these trials revealed an estimated 9% absolute improvement in survival at 4 years with the addition of docetaxel to standard of care. 76 Thus, it would seem reasonable to investigate the role of chemotherapy with ADT and RP/RT in the very-high-risk setting. Multiple phase I and II trials evaluated the role of taxane-based chemotherapy in high-risk locally advanced prostate cancer given either as neoadjuvant treatment before RP/ RT [77] [78] [79] [80] [81] [82] or combined with ADT and RT as part of a tri-modal approach. [83] [84] [85] [86] [87] Neoadjuvant chemotherapy resulted in a median tumor volume reduction of 46% and pathological downstaging in 48% of patients, 81 whereas pathological complete response was never achieved. [77] [78] [79] 82 Although its clinical advantage remains dubious, these studies demonstrated the feasibility of utilizing chemotherapy before surgery with an acceptable toxicity.
Several randomized phase III trials evaluated the role of adjuvant chemotherapy after definitive local treatment in highrisk prostate cancer (Table 3) . 75, [88] [89] [90] [91] The RTOG 9902 trial assessed whether the addition of paclitaxel, estramustine and oral etoposide would improve survival in high-risk prostate cancer patients treated with combined RT and long-term ADT. The 10-year results revealed no difference in outcome, controlling for tumor stage, Gleason score and pre-treatment PSA. Furthermore, the trial was terminated prematurely due to a high rate of thromboembolic events in the chemotherapy arm. 88 Contrary, contemporary studies demonstrated a possible benefit favoring the use of chemotherapy. 75, 90, 91 In a subset of patients with nonmetastatic high-risk locally advanced tumors comprising part of the STAMPEDE cohort, docetaxel improved failure-free survival (HR 0.60; 95% confidence interval 0.45-0.80; Po0.001); however, OS analyses were underpowered. 75 The GETUG 12 trial evaluated the addition of docetaxel and estramustine to adjuvant ADT in high-risk localized prostate cancer treated surgically. The 8-year recurrence-free survival was 62% in the combined group compared with 50% in the ADT-only group (P = 0.017). 90 Recently, initial results of the RTOG 0521 trial, evaluating the merits of adding docetaxel and prednisone to long-term RT/ADT in high-risk patients were reported. At a median follow-up of 5.5 years, the addition of chemotherapy was associated with improved overall and diseasespecific survival with acceptable toxicity. 91 Thus, while it seems chemotherapy may have an important role as part of multimodal treatment in very high-risk prostate cancer, further studies and longer follow-up are required to evaluate the true role of adjuvant chemotherapy in this setting. 76 Treatment of the primary tumor in patients with pelvic lymph node involvement Historically, the administration of local therapy to the primary tumor in men with pelvic lymph node involvement was deemed futile. However, indirect evidence suggests clear benefit to optimal control of the primary tumor in the setting of regional lymph node metastasis ( Table 3) .
The advantage of adding RT to androgen deprivation in patients with pathological node-positive disease recognized at RP has been demonstrated in several studies. 92, 93 In an attempt to identify the optimal treatment of clinically node positive disease, Rusthoven et al. evaluated 796 patients with clinical T1-4N1M0 prostate cancer, 43% of whom were treated with external beam RT. Albeit limited by the inherent bias of a retrospective analysis, the 10-year estimated OS was 45% for those treated with RT compared with 29% in those who received no local therapy; CSS rates were 67% vs 53% (Po0.001). 94 Similar findings were observed by Lin et al. who evaluated a group of 3540 patients with clinically lymph nodepositive prostate cancer from the National Cancer Data Base. Approximately 32% of patients were treated with ADT alone, while 51% received ADT+RT. Using propensity score matching, treatment with ADT+RT was associated with a 50% decrease in 5-year allcause mortality when compared with treatment with ADT alone (HR 0.5; 95% confidence interval 0.37-0.67; Po0.001). 95 Finally, Jhonstone et al. reported on a group of 77 patients with clinical stage T4 and regional lymph node involvement in which the combination of surgery, RT and/or hormonal therapy conferred the most superior outcome compared with either therapy alone. 44 Altogether, these studies suggest the more aggressive the local control, the better the outcome.
CONCLUSION
Various criteria may be used to define very high-risk prostate cancer. The paradigm of deeming patients with truly high-risk disease unfit for surgical treatment needs to be revisited. Men with locally advanced tumors may gain benefit from modern imaging techniques and local control by either RP or RT, while those with node-positive disease may benefit from local definitive treatment in the setting of a multimodal regimen, offering cure in well-selected patients. Further studies are necessary to better characterize the very-high-risk tumors and determine the optimal therapy for the individual patient.
